1ST WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE 2006

A GLOBAL PERSPECTIVE
May 31 – June 4, 2006, Stockholm, Sweden

Program

Patron of the 1st World Psoriasis & Psoriatic Arthritis Conference is His Majesty King Carl Gustav

www.ifpa-pso.org
A GLOBAL PERSPECTIVE – 1ST WORLD PSORIASIS & PSORIATIC ARTHRITIS CONFERENCE 2006

Welcome
- IFPA President
- Chairmen of the Scientific Committee
Committees
Program at a glance
Scientific program
Registration & Accommodation
Social program
General information
Important addresses
Map Stockholm
Abstract titles

page 3
page 3
page 4
page 5
page 6
page 8
page 14
page 14
page 15
page 15
page 17
page 18
Dear friends,

On behalf of IFPA it is my great honour to welcome you to Stockholm and the 1st World Psoriasis & Psoriatic Arthritis Conference.

Delegates from all over the world have registered from more than 40 countries. Speakers and abstract authors represent researchers, clinicians and patients.

We are proud to present to you a broad scientific program covering both the dermatology and rheumatology aspects of the psoriasis disease. Hopefully this conference will generate a spirit of partnership to improve the understanding and care of psoriasis patients and to bring all aspects of psoriasis together in order to achieve a comprehensive view of treatment methods and quality of life issues.

You are welcome to attend several social events. The City of Stockholm and the Stockholm County Council invite us all to a reception in the beautiful City Hall, which I hope that you will all attend. Hopefully you will take some extra time to explore our beautiful city and I wish you an enjoyable stay in Stockholm.

I want to express my gratitude to all involved in launching this conference, especially the scientific committee and council, our sponsors and the organizing committee.

Yours sincerely,

Lars Ettarp
President of IFPA
DEAR COLLEAGUE,

Welcome to the 1st World Psoriasis and Psoriatic Arthritis Conference 2006. We hope you enjoy your stay in Stockholm and benefit from this first meeting of the psoriasis community from around the world. Medical professionals from both dermatology and rheumatology, and from many different countries, are here to study the most recent advances in four basic areas of research in psoriatic disease: clinical research, including therapy and epidemiology; genomics and proteomics; immunology and cell biology; and quality of life. We anticipate that you will also take home a much greater global perspective of psoriasis treatments, access to care and research needs.

Along with the International Federation of Psoriasis Associations, we are eager for clinicians, researchers and psoriasis association leaders to foster ongoing communication so that future research and advocacy initiatives can take form – a partnership that will make a significant difference to psoriasis patients throughout the world.

We also want to thank the corporate sponsors for their support in helping make this conference a reality. They, too, are an important part of improving the lives of the millions of people who live with psoriasis and psoriatic arthritis worldwide.

Thank you for joining us at this first world conference. We are pleased you are here.

Sincerely,

Mark Lebwohl, M.D.
IFPA Medical Advisor & Honorary Chairman
Kenneth Gordon, M.D.
Co-Chair Dermatology Scientific Committee
Philip Mease, M.D.
Co-Chair Rheumatology Scientific Steering Committee
Scientific Steering Committee

Honorary Chairman, 1st World Psoriasis & Psoriatic Arthritis Conference 2006
Mark Lebwohl, M.D., USA

CLINICAL RESEARCH
Kenneth Gordon, M.D., Co-Chairman - Dermatology, USA
Philip Mease, M.D., Co-Chairman - Rheumatology, USA

GENOMICS & PROTEOMICS
Jonathan Barker, B.Sc. M.D FRCP, UK
Dafna Gladman, M.D., FRCP, Canada

QUALITY OF LIFE
Peter van de Kerkhof, M.D., Ph.D., The Netherlands
Alan Menter, M.D., USA
Douglas J. Veale, M.D., FRCPI, FRCP (Lon) Ireland

IMMUNOLOGY & BIOLOGY
Christopher Ritchlin, M.D., USA
Mona Ståhle, M.D., Ph.D., Sweden

Scientific Council
Dominique Baeten, M.D., Ph.D., The Netherlands
Michael David, M.D., Israel
Steven Feldman, M.D., Ph.D., USA
Andrew Y. Finlay, FRCP, UK
Oliver FitzGerald, M.D., Ireland
Ibrahim Hassan Galadari, M.D., United Arab Emirates
Philip Helliwell, M.D., UK
Arthur Kavanaugh, M.D., USA
Juha Kere, M.D., Ph.D., Sweden
Tae Yoon Kim, M.D., South Korea
John Y. M. Koo, M.D., USA
Gerald G. Krueger, M.D., USA
Iain B. Mclnnes, Ph.D., FRCP, UK
Peter Nash, M.D., Australia
Frank Nestle, M.D., UK
Brian Nickoloff, M.D., Ph.D., USA
Jean-Paul Ortonne, M.D., France
Joerg C. Prinz, M.D., Germany
Proton Rahman, M.D., Canada
Paul P. Tak, M.D., Ph.D., The Netherlands
Gail Todd, M.D., Ph.D., South Africa
Kurt de Vlam, M.D., Ph.D., Belgium

Organizing Committee
Lars Ettarp, President of IFPA
President of Swedish Psoriasis Association, Sweden

Gail Zimmerman, Vice President of IFPA,
President & CEO, National Psoriasis Foundation, USA

Sheri Decker, Secretary of IFPA
International Relations, National Psoriasis Foundation, USA

Jan A. Monsbakken, Treasurer of IFPA
Secretary General, Norwegian Psoriasis Association, Norway

Birgitta Rehnby, Executive Director,
Swedish Psoriasis Association, Sweden

Hoseah Waweru, M.D., Member At Large of IFPA
President, Psoriasis Association of Kenya, Kenya

Abstract Secretariat
Liz Horn, Ph.D., National Psoriasis Foundation, USA
### WEDNESDAY MAY 31

**All meetings held at Norra Latin**

- **9:00 – 19:00** Meetings of international research consortia and subcommittees
- **15:00 – 19:00** Registration
- **18:30 – 22:00** Exhibition installation
- **19:00** Welcome reception

### THURSDAY JUNE 1

**All meetings held at Folkets Hus**

- **7:30** Registration
- **8:30 – 9:00** Opening Ceremony
- **9:00 – 11:30** Genomics & Proteomics  
  *Chairs: Drs. Jonathan Barker and Dafna Gladman: Ps and PsA speakers*
- **9:00 – 11:00** Clinical Research Session for Allied Health Professionals
- **11:30 – 14:00** Lunch/Posters/Exhibits
- **12:30 – 14:00** Wyeth Satellite Symposium
- **14:00 – 17:00** Immunology & Biology  
  *Chairs: Drs. Mona Ståhle and Christopher Ritchlin: Ps and PsA speakers*
- **14:00 – 16:00** Genetics Session for Allied Health Professionals
- **17:00 – 18:30** LEO Pharma Satellite Symposium

### FRIDAY JUNE 2

**All meetings held at Folkets Hus**

- **8:00 – 9:00** Poster Session/Exhibits
- **9:00 – 11:30** Quality of Life (Burden of the Disease)  
  *Chairs: Drs. Peter van de Kerkhof and Douglas Veale: Ps and PsA speakers*
- **11:30 – 14:00** Lunch/Posters/Exhibits
- **12:30 – 14:00** Serono Satellite Symposium
- **14:00 – 17:00** Global Perspective of Psoriasis  
  *Chairs: Lars Ettarp, Gail Zimmerman, Mark Lebwohl, M.D.*  
  *Medical professionals and psoriasis association representatives from various continents will review: magnitude of the problem; stigmatization; access to care and status of research*
- **19:00** Reception at Stockholm City Hall  
  *(hosted by the City of Stockholm and the Stockholm County Council)*
A GLANCE

SATURDAY JUNE 3
All meetings held at Folkets Hus

8:00 – 9:00 Poster Session/Exhibits
9:00 – 11:30 Clinical Research: Natural History, Disease History and Epidemiology
   Chairs: Drs. Kenneth Gordon and Philip Mease: Ps and PsA speakers
9:00 – 11:00 Immunology and Biology for Allied Health Professionals
11:30 – 14:00 Lunch/Posters/Exhibits
14:00 – 16:00 Clinical Research continued
   Chairs: Drs. Kenneth Gordon and Philip Mease: Ps and PsA speakers
19:30 Conference Dinner at Restaurant Solliden, Skansen
   (buses depart from Folkets Hus at 19:00 hrs)

SUNDAY JUNE 4
All meetings held at Norra Latin

9:30 – 14:30 Advocacy Session
   Lunch included
   Chairs: Lars Ettarp, Gail Zimmerman
   International review of patient rights and needs
14:30 – 17:00 IFPA Meeting for member associations
17:00 – 19:00 EUROPSO Meeting

MONDAY JUNE 5
All meetings held at Norra Latin

9:00 – 17:00 World Psoriasis Day, October 29
   WPD Supporters Meeting
   Psoriasis Associations and others
### WEDNESDAY MAY 31

All meetings held at Norra Latin

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 – 10:00</td>
<td>IFPA Organizing Committee Meeting</td>
<td>460</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>IFPA Scientific and Organizing Committee Meeting</td>
<td>460</td>
</tr>
<tr>
<td>13:00 – 17:00</td>
<td>GRAPPA Meeting Chair, Philip Mease, M.D.</td>
<td>Musiksalen</td>
</tr>
<tr>
<td>17:00 – 19:00</td>
<td>ImmunoHistology Meeting Chair, Oliver Fitzgerald, M.D.</td>
<td>Musiksalen</td>
</tr>
<tr>
<td>15:00 – 19:00</td>
<td>Registration</td>
<td>Outside Musiksalen</td>
</tr>
<tr>
<td>18:30 – 22:00</td>
<td>Exhibition Installation</td>
<td>Folkets Hus</td>
</tr>
<tr>
<td>19:00 – 21:00</td>
<td>Welcome Reception</td>
<td>Ljusgården</td>
</tr>
</tbody>
</table>

### THURSDAY JUNE 1

All meetings held at Folkets Hus

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30</td>
<td>Registration</td>
<td>Folkets Hus, top floor</td>
</tr>
<tr>
<td>8:00 – 9:00</td>
<td>Coffee Coffee will be served on the premises</td>
<td></td>
</tr>
<tr>
<td>8:30 - 9:00</td>
<td>Opening Ceremony Lars Ettarp, President, International Federation of Psoriasis Associations (IFPA), Stockholm, Sweden Mark Lebwohl, MD, Honorary Chairman, 1st World Psoriasis and Psoriatic Arthritis Conference 2006, New York City, NY, United States Professor Hans Wigzell, Chief Scientific Advisor to the Swedish Government and Former Chairman of the Nobel Committee for Medicine, Stockholm, Sweden</td>
<td>A/B</td>
</tr>
<tr>
<td>9:00 – 11:30</td>
<td>GENOMICS &amp; PROTEOMICS Chairmen: Jonathan Barker, M.D., and Dafna Gladman, M.D.</td>
<td>A/B</td>
</tr>
<tr>
<td>9:00 – 10:00</td>
<td>Introduction and overview – invited lectures • Genetics of psoriasis. Jonathan Barker, M.D., London, England, United Kingdom (9:00 – 9:30) • Genetics of psoriatic arthritis. Proton Rahman, M.D., St. Johns, Newfoundland, Canada (9:30 – 10:00)</td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:50</td>
<td>Abstract presentations 9 - HLA-Cw*0602 and HLA-ER genotypes interact in psoriasis. (10:00 – 10:10) 11 - Role of chromosome 6P haplotypes in the susceptibility to psoriatic arthritis. (10:10 – 10:20) 6 - Follow-up analysis of PSORS9 in Chinese families: Refine the critical interval to chromosome 4q31-32 and provide strong linkage evidence for early onset patients by order subset analysis. (10:20 – 10:30) 10 - Characterizing susceptibility to phenotypic variations of psoriasis by comparing allelic association signals on PSORS loci chromosomes. (10:30 – 10:40) 13 - Epidemiology of psoriasis: A study of 156 California twin pairs. (10:40 – 10:50)</td>
<td></td>
</tr>
<tr>
<td>9:00 – 11:00</td>
<td>Clinical Research Session for Allied Health Professionals Psoriasis Association Leaders and Media Chairmen: Kenneth Gordon, M.D., and Philip Mease, M.D.</td>
<td>C</td>
</tr>
<tr>
<td>11:30 – 14:00</td>
<td>Lunch/Posters/Exhibits Lunch is served in restaurant Cabaret</td>
<td>C</td>
</tr>
<tr>
<td>12:30 – 14:00</td>
<td>Wyeth Satellite Symposium</td>
<td>C</td>
</tr>
</tbody>
</table>
### PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Hall</th>
</tr>
</thead>
</table>
| 14:00 – 17:00 | IMMUNOLOGY & BIOLOGY  
Chairmen: Mona Ståhle, M.D., Ph.D., and Christopher Ritchlin, M.D. | A/B    |
| 14:00 – 15:00 | Introduction and overview - invited lectures  
- Novel insights into early triggers of psoriasis pathogenesis. Frank Nestle, M.D., London, England, United Kingdom (14:00 – 14:20)  
- Immunobiology of psoriasis. Joerg Prinz, M.D., Munich, Germany (14:20 – 14:40)  
- Immunobiology of psoriatic arthritis. Christopher Ritchlin, M.D., Rochester, NY, United States (14:40 – 15:00) | A/B    |
| 15:00 – 16:30 | Abstract Presentations  
- Substance P and its receptor neurokinin-1 in psoriasis: A pathoetiological role? (15:00 – 15:15)  
- Regulation of 12-LOX gene expression by insulin-like growth factor-II promote cell proliferation through ERK and PI3K-PKC pathway in human keratinocytes. (15:15 – 15:30)  
- Are the pathogenic T cells in psoriasis generated in the tonsils and what are they reacting to in the skin? (15:30-15:45)  
- Ectopic lymphoid neogenesis in psoriatic arthritis. (15:45 – 16:00)  
- Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. (16:00 – 16:15)  
- Novel innate response cytokines in psoriatic arthritis. (16:15 – 16:30) | A/B    |
| 16:30 – 17:00 | Invited lecture  
- Animal models of psoriasis. Brian Nickoloff, M.D., Ph.D., Chicago, IL, United States | A/B    |
| 14:00 - 16:00 | Genetics Session for Allied Health Professionals  
Psoirasis Association Leaders and Media  
Chairmen: Dafna Gladman, M.D., and Jonathan Barker, M.D. | C      |
| 17:00 – 18:30 | LEO Pharma Satellite Symposium | C      |

---

**FRIDAY JUNE 2**  
_all meetings held at Folkets Hus_

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Hall</th>
</tr>
</thead>
</table>
| 8:00 – 9:00   | Poster Session and Exhibits  
_Coffee will be served on the premises_ | A/B    |
| 9:00 – 11:30  | QUALITY OF LIFE (BURDEN OF THE DISEASE)  
Chairmen: Peter van de Kerkhof, M.D., Ph.D., and Douglas Veale, M.D. | A/B    |
| 9:00 – 9:10   | Welcome and introduction  
- Dermatology quality of life. Andrew Finlay, M.D., Cardiff, Wales, United Kingdom (9:00 – 9:05)  
- Rheumatology quality of life. Arthur Kavanaugh, M.D., San Diego, CA, United States (9:05 – 9:10) | A/B    |
| 9:10 – 10:20  | Abstract presentations  
Patient Surveys  
- Psoriasis impacts daily life and carries a substantial burden: National Psoriasis Foundation Survey Panels. (9.10 – 9:20)  
- Psoriatic arthritis: Patient knowledge and its relationship to quality of life. (9:20 – 9:30)  
New Measurements  
- The World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) as a framework for understanding the manifestations and consequences of psoriasis and psoriatic arthritis. (9:30 – 9:40)  
**Friday June 2 continues**

**Interviews**

39 - Revealing the extensive secondary impact of psoriasis on family members. (9:50 – 10:00)

41 - Stress and psoriasis: A reciprocal relationship? (10:00 – 10:10)

43 - Factors accounting for quality of life in psoriasis patients. (10:10 – 10:20)

10:20 – 11:30

**Invited lectures**

49 - Quantitative assessment on adherence to medication: Implications for treatment. (10:20 – 10:40)

Steven Feldman, M.D., Ph.D., Winston-Salem, NC, United States


- Quality of life in dermatology. Andrew Finlay, M.D., Cardiff, England, United Kingdom (11:00 – 11:15)

- Quality of life related issues in psoriatic arthritis. Arthur Kavanaugh, M.D., San Diego, CA, United States (11:15 – 11:30)

11:30 – 14:00

**Lunch/Posters/Exhibits**

*Lunch is served in restaurant Cabaret*

12:30 - 14:00

**Serono Satellite Symposium**

14:00 – 17:00

**Global Perspective of Psoriasis**

Chairmen: Mark Lebwohl, M.D., Lars Ettarp and Gail Zimmerman

- Gaining a global perspective of psoriasis
  
  Mark Lebwohl, M.D., New York City, NY, United States (14:00 – 14:10)

  **Invited Lectures**

  - Burden of disease: EUROPSO Survey
    
    Jean Paul Ortonne, M.D., Nice, France (14:10-14:40)

  - Question and answer (14:40 – 14:50)

  - Burden of disease: U.S. 2001 Benchmark Survey
    
    Steven Feldman, M.D., Ph.D., Winston-Salem, NC, United States (14:50 – 15:20)

  - Question and answer (15:20 – 15:30)

- International insights into psoriasis

  - South Africa. Gail Todd, M.D., Capetown (15:30 – 15:40)

  - United Arab Emirates. Ibrahim Hassan Galadari, M.D., Dubai (15:40 – 15:50)

  - Argentina. Silvia Fernandez Barrio, Buenos Aires (15:50 – 16:00)

  - South Korea. Tae-Yoon Kim, M.D., Seoul (16:00 – 16:10)

  - Kenya. Hoseah Waweru, M.D., Nairobi (16:10 – 16:20)

  - Israel. Michael David, M.D., Petah Tiqwa (16:20 – 16:30)

- Discussion

  - Working to develop an international agenda on behalf of psoriasis patients.
    
    Lars Ettarp, Stockholm, Sweden, and Gail Zimmerman, Portland, OR, United States (16:30 – 17:00)

19:00 – 21:00

**Reception at Stockholm City Hall**

(individual transport to and from)

---

**SATURDAY JUNE 3**

*All meetings held at Folkets Hus*

**Poster Session and Exhibits**

*Coffee will be served on the premises*

**9:00 – 11:30**

**NATURAL HISTORY, DISEASE HISTORY AND EPIDEMIOLOGY**

Chairmen: Kenneth Gordon, M.D. and Philip Mease, M.D.

**Keynote lecture**

- Historical perspective on psoriasis. TBD (9:00 – 9:20)
<table>
<thead>
<tr>
<th>Time</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:20 – 10:20</td>
<td><strong>Invited lectures</strong></td>
</tr>
<tr>
<td></td>
<td>• New elements of epidemiology and co-morbidities of psoriasis revisited.</td>
</tr>
<tr>
<td></td>
<td>Gerald G. Krueger, MD, Salt Lake City, UT, United States (9:20 – 9:40)</td>
</tr>
<tr>
<td></td>
<td>• Outcome measure science of psoriasis.</td>
</tr>
<tr>
<td></td>
<td>Robert Chalmers, MD, Manchester, England, United Kingdom (9:40 – 9:50)</td>
</tr>
<tr>
<td></td>
<td>• New elements of epidemiology and clinical aspects of psoriatic arthritis.</td>
</tr>
<tr>
<td></td>
<td>Dafna Gladman, M.D., Toronto, Ontario, Canada (9:50 – 10:10)</td>
</tr>
<tr>
<td></td>
<td>• Panel discussion.</td>
</tr>
<tr>
<td></td>
<td>Moderator: Kenneth Gordon, M.D., Chicago, IL, United States (10:10 – 10:20)</td>
</tr>
<tr>
<td>10:20 – 11:30</td>
<td><strong>Abstract presentations</strong></td>
</tr>
<tr>
<td></td>
<td>58 - Hormonal effects of pregnancy on psoriasis. (10:20 – 10:30)</td>
</tr>
<tr>
<td></td>
<td>56 - Childhood psoriasis: A study of 277 patients from China. (10:30 – 10:40)</td>
</tr>
<tr>
<td></td>
<td>72/96 - 72 Diagnosis of arthritis in psoriasis patients presenting with joint pain to a dermatology/rheumatology clinic.</td>
</tr>
<tr>
<td></td>
<td>74/77 - 74 Magnetic resonance imaging in dactylitis: What is the site of the inflammation?</td>
</tr>
<tr>
<td></td>
<td>77 - A new enthesis index for psoriatic arthritis. (10:50 – 11:00)</td>
</tr>
<tr>
<td></td>
<td>112 - Disease activity in early psoriatic arthritis: A prospective comparative study with rheumatoid arthritis. (11:00 – 11:10)</td>
</tr>
<tr>
<td></td>
<td>97 - Classification criteria for psoriatic arthritis: Results from the CASPAR study. (11:10 – 11:20)</td>
</tr>
<tr>
<td></td>
<td>106 - Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. (11:20 – 11:30)</td>
</tr>
<tr>
<td>9:00 – 11:00</td>
<td><strong>Immunology and Biology Session for Allied Health Professionals</strong></td>
</tr>
<tr>
<td></td>
<td>Psoriasis Association Leaders and Media</td>
</tr>
<tr>
<td></td>
<td>Chairmen: Mona Ståhle, M.D., Ph.D., and Christopher Ritchlin, M.D.</td>
</tr>
<tr>
<td>11:30 – 14:00</td>
<td><strong>Lunch/Posters/Exhibits</strong></td>
</tr>
<tr>
<td></td>
<td>Lunch is served in restaurant Cabaret</td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td><strong>CLINICAL RESEARCH</strong></td>
</tr>
<tr>
<td></td>
<td>Chairmen: Kenneth Gordon, M.D., and Philip Mease, M.D.</td>
</tr>
<tr>
<td>14:00 – 14:40</td>
<td><strong>Invited lectures</strong></td>
</tr>
<tr>
<td></td>
<td>• Traditional systemic agents and biologic agents in psoriasis.</td>
</tr>
<tr>
<td></td>
<td>Kristian Reich, M.D., Göttingen, Germany (14:00 – 14:20)</td>
</tr>
<tr>
<td></td>
<td>• Traditional systemic agents in psoriatic arthritis.</td>
</tr>
<tr>
<td></td>
<td>Neil McHugh, M.D., Bath, England, United Kingdom (14:20 – 14:30)</td>
</tr>
<tr>
<td></td>
<td>• Biologic agents in psoriatic arthritis.</td>
</tr>
<tr>
<td></td>
<td>Philip Mease, M.D., Seattle, WA, United States (14:30 – 14:40)</td>
</tr>
<tr>
<td>14:40 – 15:10</td>
<td><strong>Abstract presentations</strong></td>
</tr>
<tr>
<td></td>
<td>117 - Results of Phase II study of CNTO 1275 in the treatment of psoriasis. (14:40 – 14:50)</td>
</tr>
<tr>
<td></td>
<td>92/93 - 92 Magnetic resonance imaging study assessing the efficacy of anakinra (Kineret) in psoriatic arthritis. 93 - Efficacy of anakinra (Kineret) in psoriatic arthritis: A clinical and immunohistological study. (14:50 – 15:00)</td>
</tr>
<tr>
<td></td>
<td>124 - Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multicenter, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis. (15:00 – 15:10)</td>
</tr>
<tr>
<td>15:10 – 15:50</td>
<td><strong>Concluding lectures</strong></td>
</tr>
<tr>
<td></td>
<td>• Drug safety in psoriasis and psoriatic arthritis.</td>
</tr>
<tr>
<td></td>
<td>Eric Ruderman, M.D., Chicago, IL, United States (15:10 – 15:30)</td>
</tr>
<tr>
<td></td>
<td>• Forward looking lecture on new treatments in development.</td>
</tr>
<tr>
<td></td>
<td>Alice Gottlieb, M.D., Ph.D., Boston, MA, United States (15:30 – 15:50)</td>
</tr>
<tr>
<td></td>
<td><strong>Panel discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Moderator: Kenneth Gordon, M.D., Chicago, IL, United States (15:50 – 16:00)</td>
</tr>
<tr>
<td>19:30</td>
<td><strong>Conference Dinner at restaurant Solliden, Skansen</strong></td>
</tr>
<tr>
<td></td>
<td>Buses will depart from Folkets Hus at 19.00 hrs</td>
</tr>
</tbody>
</table>
SUNDAY JUNE 4  
All meetings held at Norra Latin

Room: Pelarsalen

9:30 – 14:30  
**AD vocacy Session**

**Audience:** Psoriasis association representatives, physicians/scientists, industry representatives and politicians working to develop an international patient advocacy agenda.

**Purpose:** This session will identify opportunities for collaboration between psoriasis patient associations, medical professionals, industry representatives and governments to promote public awareness and access by all patients with psoriasis and psoriatic arthritis to safe and effective treatment. These actions will promote better understanding of psoriasis and psoriatic arthritis, and educate health professionals, scientists, insurers, government officials, professional societies, media and the public about the burden of these diseases and need for treatment.

9:30 – 12:00  
**Invited Lectures**

- Welcome and introduction.  
  Lars Ettarp, President of IFPA, Gail Zimmerman, Vice President of IFPA
- How Patient Advocacy Organizations can Help Physicians Help Patients.  
  Mark Lebwohl, M.D., New York City, NY, United States (10:00 – 10:15)
- Physician’s perspective of advocacy.  
  Steven Feldman, M.D., Ph.D., Winston-Salem, NC, United States (10:15 – 10:35)
- Industry’s perspective of advocacy.  
  Rajesh Gupta, Serono, Inc., Geneva, Switzerland (10:35 – 11:00)

11:00 – 11:30  
**Coffee**

11:30 – 13:00  
**Panel Discussion and Open Forum**  
Chairmen: Lars Ettarp and Gail Zimmerman

13:00 – 14:00  
**Lunch**

14:00 – 14:30  
**Summary and conclusion**  
Lars Ettarp and Gail Zimmerman

**Audience participation to address these issues:**
- Why do we need advocacy?
- What are examples of effective and successful advocacy initiatives in action?
- Who is doing what from associations, medical community, corporations and government?
- How can different factions cooperate?
- What aims are the most important for advocacy?
- What will it take to become an effective advocacy organization?

14:30 – 17:00  
**IFPA Annual Meeting for Member Associations**  
Pelarsalen

14:30  
Coffee

15:00  
Meeting starts

17:00 – 19:00  
**EuroPsy Meeting for Member Associations**  
Room: 255

MONDAY JUNE 5  
All meetings held at Norra Latin

9:00 – 17:00  
World Psoriasis Day, October 29  
WPD Supporters Meeting  
Psoriasis Associations and others
Indications: Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA. Design and administration: Therapy with Raptiva should be initiated by a physician specialised in dermatology. Subcutaneous injection: Initial single dose of 0.7 mg/kg body weight, followed by weekly injections of 1.0 mg/kg body weight (maximum single dose should not exceed a total of 200 mg).

Dosage and administration: Subsequent doses: 1 mg/kg, volume to be injected per 10 kg body weight = 0.07 ml, volume to be injected per 10 kg body weight = 0.1 ml. The duration of therapy is 12 weeks. Therapy may be continued only in patients who responded to treatment (PGA good or better). Not to be used in patients who are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA. Dosage and administration: Therapy with Raptiva should be initiated by a physician specialised in dermatology. Subcutaneous injection: Initial single dose of 0.7 mg/kg body weight, followed by weekly injections of 1.0 mg/kg body weight. The duration of therapy is 12 weeks. Therapy may be continued only in patients who responded to treatment (PGA good or better). Not to be used in patients who are intolerant to other systemic therapies including cyclosporine, methotrexate and PUVA.

Contraindications: Hypersensitivity to efalizumab or to any of the excipients. History of malignancies. Active tuberculosis and other severe infections. Patients with history of clinically significant immunodeficiencies. Prescribing Information: Raptiva® 100 mg/kg powder and solvent for injection containing 125 mg efalizumab, plus preservatives. For intramuscular and subcutaneous use only. Use only if the vial is unopened and free from physical contamination. Use of reconstituted product is not recommended. Place vial immediately after first opening and reconstitution.

Precautions: Raptiva may affect host immune defenses. Patients should be counselled to seek medical advice before receiving any other vaccine. If potential infection occurs during treatment, Raptiva should be discontinued. Vaccination with live vaccines is contraindicated during treatment. Use with caution in patients with history of clinically significant infections. Treatment during pregnancy should be monitored, and according to severity, Raptiva should be discontinued. In responders: Transient nausea, fever, flu-like symptoms, headache, chills, myalgia, elevation of ALT, AST. In all patients: Transient erythema, urticaria, injection site reactions, and mild to moderate headaches, fever, nausea.

References:
REGISTRATION

For on-site registrations and/or questions, please contact the registration desk. The registration desk will open up on May 31 at 15.00 hrs (3 p.m.) and will remain open all through the conference. The registration desk on May 31 is at the venue Norra Latin. The conference registration desk on June 1, 2 and 3 is held at the venue Folkets Hus.

On Sunday June 4 an “Information desk” will be located outside the session hall ‘Pelarsalen’ at the venue Norra Latin.

REGISTRATION FEES
According to Sixth VAT Directive, 77/388/EEG, Article 9.2.(e), participants from different countries should pay their registration fee either including or excluding Swedish VAT. For VAT details, please contact the registration desk.

FEES
On site fee from May 29

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delegates</td>
<td>SEK 5200 / 6500</td>
</tr>
<tr>
<td>Students* and IFPA Members</td>
<td>SEK 2750 / 3438</td>
</tr>
</tbody>
</table>

* Student fee: Please include letter of introduction from your department chairman or program director with your registration form.

Accompanying person fee
Fee includes 25% VAT
SEK 1875

DELEGATE FEE COVERS
Participation in the sub-committee & GRAPPA meetings, satellite symposium, conference sessions, welcome reception, exhibition, morning and afternoon coffees, lunches, poster sessions and the Stockholm City Hall reception and subsidized conference dinner.

ACCOMPANYING PERSON’S FEE COVERS
Participation in the welcome reception, poster session, the Stockholm City Hall reception and subsidized conference dinner.

PAYMENT
Please contact the registration desk for any questions regarding your payment.

ACCOMMODATION
Please contact the registration desk for any questions regarding your hotel accommodations. The official conference hotels are: Best Western Wallin Hotel, Comfort Hotel Stockholm, Nordic Sea Hotel, Sheraton Stockholm and Hotel Tegnérlunden. All hotels are within walking distance to the conference venues.

SOCIAL PROGRAM

- A ticket is mandatory for entrance to the Stockholm City Hall and to the Conference Dinner at Skansen
- The tickets are included in your ‘delegate kit’ you receive at the registration desk
- For bookings and/or questions, please contact the registration desk

WEDNESDAY MAY 31 at 19:00 hrs, WELCOME RECEPTION
The Welcome Reception takes place at the venue Norra Latin. A perfect opportunity to mingle with your colleagues while you are served light snacks, a glass of wine or a soft drink. Included in the registration fee for delegates and accompanying guests.

FRIDAY JUNE 2 at 19:00 hrs, RECEPTION, STOCKHOLM CITY HALL
The City of Stockholm and the Stockholm County Council invite you to a buffet dinner at the Stockholm City Hall. Beautifully situated on the waterfront of Riddarfjärden in central Stockholm. The Stockholm City Hall is mostly famous for the Nobel Prize festivities, which take place in the Blue Hall every year on December 10. Please bring the invitation card included in your ‘delegate kit.’ Individual transport to and from the City Hall that is located approximately within 15 minutes walking distance from the conference venue.

SATURDAY JUNE 3 at 19:30 hrs, CONFERENCE DINNER AT SOLLIDEN, SKANSEN
The conference dinner will be held at restaurant Solliden at Skansen. Skansen - across the water on the island of Djurgården - was founded in 1891 and is the world’s oldest open-air museum. Bus will depart from Folkets Hus, 19:00. Please bring your ticket!
Badges
The participant's name badge will be provided at the registration desk. For security reasons, all participants are requested to wear the badge throughout the conference.

Business hours and shopping
Shops are open between 10.00 and 18.00 hrs on weekdays and from 10.00 to 15.00 hrs on Saturdays. Shops in the City centre have extended opening hours, some even on Sundays between 12.00 and 16.00 hrs. The main shopping streets in the centre of Stockholm are: Hamngatan, Biblioteksgatan, Drottninggatan and Västerlånggatan in the Old Town.

Certificate
A Certificate of Attendance will be issued on request at the registration desk on the last day of the conference.

CME Credits
The Institute for professional development of physicians in Sweden, IPULS, has reviewed and approved the symposium "1st World Psoriasis and Psoriatic Arthritis Conference 2006," May 31- June 4 in Stockholm, Sweden. A maximum of 17.5 CME credit hours may be awarded for participation in the complete conference.

Currency
The currency in Sweden is the Swedish krona, SEK.

Exhibition
The exhibiting companies are:
Abbott Laboratories
Evaux Laboratoires
LEO Pharma
Natural Cosmetics
Schering-Plough
Serono Nordic
Wyeth AB

The Exhibition will be open for delegates from June 1, at 09.00 hrs and stay open throughout the Conference. Opening hours will be Thursday - Friday 09.00-17.30 hrs and on Saturday 09.00-16.30 hrs.

Insurance
Neither the Conference Organizers or the Conference Secretariat accept any liability for personal injuries sustained, or for loss or damage to property belonging to conference participants, either during or as a result of the conference.

Language
The conference language is English. There will be no simultaneous interpretation.

Meals
Morning and afternoon coffee will be served on the premises. Lunches on Thursday, Friday and Saturday will be served at the restaurant Cabaret.

Official Airline
SAS has been appointed Official Airline for the 1st World Psoriasis & Psoriatic Arthritis Conference 2006 and offers a special conference rate. To obtain SAS conference fares kindly contact your nearest SAS office and quote the reference number: SE0604. Telephone numbers for the SAS call center in Sweden: 0770 727 727

Press
Authorized members of the press are welcome to cover the 1st World Psoriasis and Psoriatic Arthritis Conference 2006. All press will be asked to show your press identification upon registration.

Speaker’s ready room
All speakers must contact the technician in room 201 (i.e. the Speaker's ready room) in good time before your scheduled presentation.

Time zone
Sweden is 2 hours ahead of Greenwich Mean Time (GMT) during the summer.

Tourist information
For tourist information about Stockholm, Sweden, please visit the web site: www.stockholmtown.com, or contact the Tourist Centre on the lower level of the Cultural Center/Kulturhuset, Sergels Torg 1. Open Monday-Friday 09.00-18.00 hrs and Sat-Sun 10.00-16.00 hrs. Phone: +46 8 789 24 90. Fax: +46 8 789 2491. E-mail: info@svb.stockholm.se

IMPORTANT ADDRESSES

CONFERENCE VENUE
Stockholm City Conference Centre, Norra Latin/Folkets Hus
CCC Norra Latin is located on Drottninggatan 71B
CCC Folkets Hus is located on Barnhusgatan 12-14
Box 70471
SE- 107 26 Stockholm, Sweden
Phone: +46 8 506 166 00

CONFERENCE & EXHIBITION SECRETARIAT
Stockholm Convention Bureau
P.O. Box 6911
SE-102 39 Stockholm, Sweden
Phone: +46 8 5465 15 00
Fax: +46 8 5465 15 99
E-mail: stocon@stocon.se

All correspondence to members of the organizing committee may be sent to the Conference Secretariat for further distribution.
Enbrel®
etanercept

To feel the water on my arms

Fast and lasting psoriasis therapy™
A Congress Venue; Folkets Hus & Norra Latin

B City Terminal, arrival for buses from Arlanda airport and Arlanda Express

C Stockholm City Hall

D Skansen

The Official Hotels booked

1 Best Western Wallin Hotel
2 Comfort Hotel Stockholm
3 Nordic Sea Hotel
4 Sheraton Stockholm Hotel
5 Hotel Tegnérlunden

Dear participant
Welcome to Scandinavia – did you earn frequent flyer points on your journey?

www.scandinavianair.net
12 Killer immunoglobulin-like receptors KIR2DS1 and KIR2DS2 are increased in siblings concordant for psoriatic arthritis.
Dafna D. Gladman, MD, FRCP, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada, Fawvda Pellet, BSc, Iva Vukic, Toronto Western Research Institute, Toronto, Ontario, Canada, Vernon T. Farewell, PhD, Institute of Public Health, Cambridge, England, Proton Rahman, MD, MSc, FRCP, Memorial University of Newfoundland, Newfoundland, Canada.

13 Epidemiology of psoriasis: A study of 156 California twins pairs.
Stefani Triff Kappel, Medical Student, University of Southern California, Los Angeles, CA, United States, Myles Cockburn, University of Southern California, Los Angeles, CA, United States, Theodore Alkousakis, Ashley Khalap, Thomas Mack, David H. Peng, University of Southern California.

14 Expression of IL-18 bind protein in monocyte and monocyte drived Langerhans cell of psoriasis.
Qiong Huang, Huashan Hospital of Fudan University, Shanghai, China.

15 Differential effects of TNF blockade on TB-induced genes and cytokines.

16 The anti-angiogenic effect of photochemotherapy in vitro.
Hui Deng, Shanghai Jiaotong University, The Sixth People's Hospital of Shanghai, Shanghai, China, Chunlin Yan, Fudan University, Huashan Hospital, Shanghai, China, Dingfen Yuan, Shanghai Jiaotong University, The Sixth People's Hospital of Shanghai, Liao Kanghuang, Fudan University, Huashan Hospital, Shanghai, China.

17 Patients with psoriatic arthritis have an increased number of lymphocytes in the duodenal mucosa in comparison with patients with psoriasis vulgaris.
Gerd Mickelsson, MD, PhD, Ulla Lindqvist, MD, PhD, Gudjon Kristjansson, MD, PhD, Ingh Pih-Lundin, PhD, Eva Haglund, PhD, University of Uppsala, University Hospital, Uppsala, Sweden.

18 Release of INF-α from stimulated cultured T lymphocytes of psoriatic patients.
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Iain Bank, MS, Sheba Medical Center, Ramat Gan, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel, Israel, Ian Bank, Sheba Medical Center, Ramat Gan, Israel.

19 The expression of VLA-1(α1β1) on T lymphocytes CD4+ and CD8+ in psoriatic patients.
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Iain Bank, MS, Sheba Medical Center, Ramat Gan, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel, Israel, Ian Bank, Sheba Medical Center, Ramat Gan, Israel.

20 Substance P and its receptor neurokinin-1 in psoriasis: A pathoetiiological role?
Klas Nordlin, MD, PhD, Charlotte Remröd, Sol-Britt Larsson-Rahm, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

21 Serotonin receptors in psoriasis.
Klas Nordlin, MD, PhD, Krister Thorsson, Student, Sol-Britt Larsson-Rahm, MD, Karolinska Institutet, Dept. of Medicine, Karolinska University Hospital, Stockholm, Sweden, Sheila Mohabbati, PhD, Upplands University, Uppsala, Sweden, Tineke Berki, PhD, University of Ptcs, Ptcs, Hungary, Mariëla Morales, PhD, National Institute on Drug Abuse, Baltimore, MD, United States, Efrran Armita, PhD, New York University, New York, NY, United States.

22 Common TCR rearrangements in psoriatic skin lesions and streptococcal angina.
Joery C. Pinz, MD, University of Munich, Munich, Germany, Laura Dilukio, University of Rome Tor Vergata, Rome, Italy, Sigrid Vollner, Petra Bensig, University of Munich, Sergio Chimienti, University of Rome Tor Vergata.

23 Detection of SERUM B-Endorphin and its significance in psoriatic patients.
Xue-qin Yang, L. You, Li-Jun Zhang, Air Force General Hospital, Beijing, China.

24 Ectopic lymphoid neogenesis in psoriatic arthritis.
Juan D. Cañete, MD, PhD, Hospital Clinic and IDIBAPS, Barcelona, Catalonia, Spain, Begoña Santiago, PhD, Hospital 12 de Octubre, Madrid, Spain, Raímon Sarmant, MD, PhD, Hospital Clinic and IDIBAPS, Beatriz Gil-Torregrosa, PhD, Hospital Clinic, Agustin García-Peñó, PhD, Hospital Clinic and IDIBAPS, Antonio Palacin, MD, Hospital Clinic, José L. Pablos, MD, PhD, Hospital 12 de Octubre.

25 Functional role for intraepidermal T cells in the development of psoriasis.
Curtin Conrad, MD, Giulia Tonel, Frank O. Nestle, MD, University Hospital of Zurich, Zurich, Switzerland.

26 Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment.
Kurt de Vlam, MD, I. Derenke, Frank P. Luyten, Rik J.U. Lories, University Hospital Leuven, Leuven, Belgium.

27 Decreased secretion of interferon α by activated peripheral blood T cells in severe psoriasis.
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel, Ian Bank, Sheba Medical Center, Ramat Gan, Israel.

28 A trend towards an increase of the VLA-1+CD8b-subset in the peripheral blood of psoriatic patients.
Eyal Vussuki, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel, Ian Bank, Sheba Medical Center, Ramat Gan, Israel.

29 Increased frequency of circulating osteoclast precursors in psoriatic patients.
Christopher Ritchlin, MD, Robert Lois, MD, Tienneng Shao, MS, Robert Durham, Edward Schwarz, PhD, University of Rochester, Rochester, NY, United States.

30 Regulation of 12-LOX gene expression by insulin-like growth factor-II promote cell proliferation through ERK and PI3K-PKC pathway in human keratinocytes.
Tae-Yoon Kim, PhD, Su-lin Kim, Hyun Yoo, Kanglimn St. Mary's Hospital, Catholic University of Korea, Seoul, South Korea.

31 Novel innate response cytokines in psoriatic arthritis.
Iain B. McInnes, MRCP, PhD, David Kane, BSc, PhD, J. Alastair Grace, BSc, PhD, University of Glasgow, Glasgow Royal Infirmary, Glasgow, Scotland, Martin Gogarty, Barry Brensigh, Oliver Fitzgerald, PhD, University College Dublin, St. Vincent's University Hospital, Dublin, Ireland.

32 Are the pathogenic T cells in psoriasis generated in the tonsils and what are they reacting to in the skin?
Helgi Valdarnson, Landsd密rti University Hospital, Reykjavik, Iceland.
19

33 Vascular endothelial growth factor in psoriatic arthropathy. 
Hamid Przepióra-Bedzak, MD, PhD, Ivona Brzosko, MD, PhD, Katarzyna Fischer, Marek Brzosko, MD, PhD, Pomeranian Medical University, Szczecin, Poland.

QUALITY OF LIFE

34 Psoriasis impacts daily life and carries a substantial burden: National Psoriasis Foundation Survey Panels. 
Elizabeth J. Horn, PhD, National Psoriasis Foundation, Portland, Oregon, United States.

35 Quality of life and quality of care in psoriasis: An initial clinical study of an international disease management programme. 
John de Korte, Academic Medical Center, Amsterdam, The Netherlands.

36 Activities of the German Psoriasis Association (DPP). 
Joachim Barth, MD, Rudolph-Vichvch-Straße 4, Borna, Saxony, Germany, Hans-Detlev Kunz, German Psoriasis Association, Hamburg, Germany.

37 The World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) as a framework for understanding the manifestations and consequences of psoriasis and psoriatic arthropathy. 
Philip Meade, MD, Swedish Medical Center, University of Washington School of Medicine, Seattle, WA, United States, W.J. Taylor, Wellington School of Medicine & Health Sciences, University of Otago, Wellington, New Zealand.

38 Koo-Menter Psoriasis Instrument & PQQL-12. 
John Koo, MD, University of California San Francisco, San Francisco, CA, United States, Alan Menter, MD, Baylor Medical Center, Dallas, TX, United States.

39 Revealing the extensive secondary impact of psoriasis on family members. 
Ahmed Eghlileb, Emily Davies, Andrew Finlay, MD, Cardiff University, Cardiff, Wales, United Kingdom.

40 Experiences from a hotline providing guidance for members of the Danish Psoriasis Association and their families. 
Ingelise Randboell, N.S., Lis Larsen Olesen, Danish Psoriasis Association, Aarhus, Denmark.

41 Stress and psoriasis: A reciprocal relationship? 
Andrea W.M. Evrs, PhD, F. Duller, M.S.W., E.W.M. Verhoesen, MS, E. de Jong, F.W. Kraaimaat, MD, J. Schalkwijk, MD, Peter C.M. van de Kerkhof, MD, Radboud University Medical Center, Nijmegen, The Netherlands.

42 Psoriasis and social stigma. 
Ray Jobling, St. John’s University, College of Pharmacy, Cambridge, United Kingdom.

43 Factors accounting for quality of life in psoriasis patients. 
Konrad Janowski, MD, PhD, Catholic University of Lublin, Lublin, Poland.

44 Variation of psoriasis impact on quality of life of patients between the years 2003-2005. 
Miquel Riera-Fibemart, PhD, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Gloria Cabeal, MD, LEO Pharma, Barcelona, Spain, Maria Joaquin Fuente, PhD, Carlos Fernández, PhD, Hospital Universitari Germans Trias i Pujol.

45 Impact of patients’ psoriasis on the quality of life of their families: Initial results from a validation study of a novel dermatology-specific measure. 
Mohammad Khurshid Azam Basi, Cardiff University, Wales College of Medicine, Cardiff, Wales, United Kingdom, Robert Su-Ho, Cardif Royal Infirmary, Cardiff University, Cardiff, Wales, United Kingdom, Andrew Finlay, MD, Cardiff University.

46 Members of the National Psoriasis Foundation: More extensive disease and better informed about treatment options. 
Tamar Nijsten, MD, Erasmus Medical College, Rotterdam, The Netherlands, Taro Rolstad, Lake Oswege, OR, United States, Steven Feldman, MD, PhD, Wake Forest University School of Medicine, Winston-Salem, NC, United States, Robert Stern, MD, Beth Israel Cosmetic Surgery Center, Chestnut Hill, MA, United States.

47 Adolescents with psoriasis and their quality of life. 
Peter Keins, Fachklinik Sylt fuer Kinder und Jugendliche, Westerland, Germany.

48 Patient reported outcomes show improvement within one week in patients with psoriasis following 24 week etanercept treatment. 

49 Quantitative assessment on adherence to medication: Implications for treatment. 
Steven Feldman, MD, PhD, Wake Forest University, Winston-Salem, NC, United States, Rajesh Balkrishnan, Ph.D., Ohio State University College of Pharmacy, Columbus, OH, United States.

50 Study of sleep quality in patients with psoriasis. 
Xue-Qin Yang, Li You, Air Force General Hospital, Beijing, China, Jin Zhang-Rui, Institute of Aviation Medicine, Beijing, China.

51 Quality of life assessment in patients with psoriasis at Hospital Kuala Lumpur. 
Norahsinik Shamudin, Chun Soo Le, Low Pek Gan, University Putra Malaysia, Kuala Lumpur, Malaysia, Suraya H. Hussein, Hospital Kuala Lumpur, Kuala Lumpur, Malaysia.

52 Psoriatic arthritis: Patient knowledge and its relation to quality of life. 
Marie O’Rourke, Oliver FitzGerald, PhD, Barry Bresnihan, Michael David, MD, Emilia Hodak, Rabin Medical Center, Neve Zohar, Israel.

53 Psoriatic arthritis patients treated with etanercept had reductions in healthcare resource utilization: Results from the experience diagnosing, understanding care, and treatment with Enbrel (educate) trial. 
J. Mark Jackson, MD, Dermatology Specialists, Louisville, KY, United States, Erin Boldt, MD, Beth Israel Deaconess Medical Center, New Orleans, LA, United States, Doro Eisen, MD, DDS, Dermatology Research Association of Cincinnati, Cincinnati, OH, United States, H. Amy Xiu, Seth R. Stevens, MD, Amgen, Inc., Thousand Oaks, CA, United States, Elaine Yu, MS, Genentech, San Francisco, CA, United States.

54 Psoriatic arthritis patients treated with etanercept reported reductions in caregiver burden and absen- teeism: Results from the experience diagnosing, understanding care and treatment with Enbrel (educate) trial. 
Jeffrey Sobell, MD, Tufts University Medical Center, Boston, MA, United States, Steven Grekin, MD, Warren, MI, United States, Elaine Yu, Genentech, San Francisco, CA, United States, J.R. Kalden, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, W. Utter, PhD, Friedrich-Alexander University, Arthur Kavanagh, MD, University of California San Diego, La Jolla CA, United States, J.R. Kalden, MD, Friedrich-Alexander University, P.L.C.M. Van Ret, PhD, Radboud University Nijmegen Medical Centre.

55 Response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of perfor- mance characteristics in two randomized, controlled trials of TNF inhibitors. 
J. Fransen, PhD, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, Christian Antoni, MD, Friedrich-Alexander University, Dept. of Medicine II, Erlangen, Germany, Philip Meade, MD, Seattle Rheumatology Associates, Seattle, WA, United States, W. Utter, PhD, Friedrich-Alexander University, Arthur Kavanagh, MD, University of California San Diego, La Jolla CA, United States, J.R. Kalden, MD, Friedrich-Alexander University, P.L.C.M. Van Ret, PhD, Radboud University Nijmegen Medical Centre.

56 Childhood psoriasis: A study of 277 patients from China. 
Xun-Jun Zhang, PhD, Xing Fan, Feng-Li Xiao, Sen Yang, Jiang-Bo Liu, Kai-Lin Yang, Yan-Hua Liang, Anhui Medical University, Hefei, Anhui, China.

57 Comparison of clinical features in familial versus sporadic psoriatic vulgaris of Chinese Han. 
Xun-Jun Zhang, PhD, Wei Li, Wei-Dong Du, Sen Yang, Feng-Li Xiao, Su-Min He, Wen-Hui Du, Anhui Medical University, Hefei, Anhui, China.

58 Hormonal effects of pregnancy on psoriasis. 
Jerry E. Murase, MD, University of California, San Francisco Medical Center, Cupertino, CA, United States, Alles Yanes, MD, PhD, Connetics Corp., Palo Alto, CA, United States.

60 Efficacy and safety of low-dose actretin for the treatment of moderate to severe plaque-type psoriasis. 
Leon Krick, MD, Physicians Skin Care, PLLC, Louisville, KY, United States, Alix Yanes, MD, PhD, Connetics Corp., Palo Alto, CA, United States.

61 Association between psoriasis, diabetes mellitus and artherosclerosis. A case control study. 
Jonathan Shapiro, Maccabi Health Services, Tel Aviv, Israel, Amnon Kohen, Kliati Health Services, Beer Sheva, Israel, Michael David, MD, Emilia Hodak, Rabin Medical Center, Petah Tikva, Israel, Vinyl Anna, Maccabi Health Services, Ramat Hasharon, Israel, Eyal Kemer, Anthony Heymman, Maccabi Health Services, Tel Aviv, Israel.

62 Echocardiographic findings according to disease activity in patients with psoriatic arthropitis. 
Hanna Przepiore-Bedzak, MD, PhD, Ivona Brzosko, MD, PhD, Malgorzata Peregud-Pogorzela, MD, PhD, Marek Brzosko, MD, PhD, Zdzislaw Komacewicz-Jach, Pomeranian Medical University, Szczecin, Poland.

63 Echocardiographic abnormalities in patients with SAPHO syndrome. 
Hanna Przepiore-Bedzak, MD, PhD, Malgorzata Peregud-Pogorzela, MD, PhD, Ivona Brzosko, MD, PhD, Marek Brzosko, MD, PhD, Zdzislaw Komacewicz-Jach, Pomeranian Medical University, Szczecin, Poland.

64 Sustained long-term clinical efficacy and safety in patients with psoriasis for up to 2.5 years on enetra- cet. 
Anca Serban, Wyeth Research, Collegeville, PA, United States, Bori Ewel, University of Alabama, Birmingham, AL, United States, Craig Leonard, MD, St. Louis University, St. Louis, MO, United States, Victoria Verwiel, MD, St. Louis University, St. Louis, MO, United States, Alice Gottlieb, MD, PhD, University of Medicine & Dentistry New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, United States, Bruce Strober, MD, PhD, Johns Hopkins University, New York, NY, United States, Peter C.M. van der Kerkhof, MD, PhD, University Hospital Nijmegen, Nijmegen, The Netherlands, Jean Faull Ortonne, MD, Hospital de Arach, Nice, France.

Anca Serban, Wyeth Research, Collegeville, PA, United States, Bori Ewel, University of Alabama, Birmingham, AL, United States, Craig Leonard, MD, St. Louis University, St. Louis, MO, United States, Victoria Verwiel, MD, St. Louis University, St. Louis, MO, United States, Alice Gottlieb, MD, PhD, University Hospital Nijmegen, Nijmegen, The Netherlands, Jean Faull Ortonne, MD, Hospital de Arach, Nice, France, Melatena Dunn, Paul Feltos, Amgen, Inc., Thousand Oaks, CA, United States.
66 Long-term treatment of four years with infliximab: A case report of a patient with severe psoriasis. Eyal Yisufski, MD, Robin Medical Center, Holon, Israel, Michael David, MD, Emilia Hodak, Rina Segal, Hanna Feurman, Rabin Medical Center, Petah Tikva, Israel.

67 Infliximab (Remicade): A new treatment alternative for severe hidradenitis suppurativa? Anne-Marie Thelen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital Geneva, Geneva, Switzerland.

68 Acute cutaneous manifestations of a Reiter’s syndrome in an adalimumab and leflunomide treated patient. Anne-Marie Thelen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital Geneva, Geneva, Switzerland.

69 Infliximab and methotrexate-resistant rebound after efalizumab (Raptiva) discontinuation. Anne-Marie Thelen, MD, Caroline Barde, MD, Jean-Hilaire Saurat, MD, University Hospital Geneva, Geneva, Switzerland.

70 Distribution of psoriasis lesions in patients with psoriatic arthritis. Anne Lene Krogstad, MD, PhD, Karen Ellen Forsyth, MD, PhD, Rikshospitalet, Oslo, Norway, Stefan K. Fieichn, MSc, PhD, Center for Functional Magnetic Resonance Imaging, Oxford University, Oxford, United Kingdom.

71 Efficacy of topical agents under hydrophilic occlusion versus unoccluded in psoriasis. John Koo, MD, University of California Psoriasis Treatment Center, San Francisco, CA, United States, Shanthi M. Colaco, MD, MA, University of California San Francisco Medical School, San Francisco, CA, United States, Priya Sivanesan, MD, Farah Malik, MD, Julie A. Letingsinger, MD, University of California Psoriasis Treatment Center.

72 Diagnosis of arthritic in psoriasis patients presenting with joint pain to a dermatology/rheumatology clinic. Elina Mody, MD, Brigham and Women's Hospital, Boston, MA, United States, Elaine Husni, MD, MPH, Cleveland Clinic, Cleveland, OH, United States, Abir Qureshi, MD, MPH, Brigham and Women's Hospital.

73 Clinical follow up 2-4 years after onset of guttate psoriasis. Katarina Walk, MD, Petra Kjellman, MD, PhD, Lotus Mallbris, MD, PhD, Per Lanson, MD, PhD, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Mona Stålhe, MD, PhD, Karolinska University Hospital, Stockholm, Sweden.

74 Magnetic resonance imaging in dactylitis: What is the site of the inflammation? Paul Healy, University of Leeds, Leeds, United Kingdom, C. Groves, R. Chandramohan, Bradford Royal Infirmary, Bradford, United Kingdom, Philip Hellwell, PhD, University of Leeds.

75 Efficacy of the two-compound product calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris: A Romanian multicentre study. I. Nedelicu, Central Clinical Emergency Military Hospital, Bucharest, Romania, D. Forisea, C. Giurceanu, Carol Davila University of Medicine & Pharmacy, Bucharest, Romania, R. Orasanu, University of Medicine & Pharmacy, Cluj Napoca, Romania.

76 Treatment of scalp psoriasis with the two-compound product calcipotriol/betamethasone dipropionate: A pilot open label. Nicoletta Cassano, MD, Gino A. Vena, MD, University of Bari Polyclinico, Bari, Italy.

77 A new enthesitis index for psoriatic arthritis. Paul Healy, Philip Hellwell, PhD, University of Leeds, Leeds, United Kingdom.

78 Calcipotriol plus betamethasone dipropionate gel is effective and safe in the treatment of scalp psoriasis (a phase II study). Colin Buckley, MD, Waterford Regional Hospital Artekken, Waterford, Ireland, Jerry Shapiro, Skin Care Centre, Vancouver, British Columbia, Canada, Seppo Saari, Polyclinic of Dermatology, Turku, Finland, Frederic Cambaillard, Hospital Nord, St. Etienne, France, Vibeke Hoffman, LEO Pharma, Ballerup, Denmark.

79 Treatment of psoriasis vulgaris with the two-compound product calcipotriol/betamethasone dipropionate followed by calcipotriol in different formulations. Nicoletta Cassano, MD, A. Miracipillo, C. Coviello, F. Loccioloso, M. Bellino, Gino A. Vena, MD, University of Bari, Bari, Italy.


81 A pooled analysis of studies with a calcipotriol/betamethasone two-compound product in severe psoriasis vulgaris. Knud Kragballe, MD, Aarhus University Hospital, Aarhus, Denmark, A. V. Anstey, Royal Gwent Hospital, Newport, Wales, United Kingdom.

82 Long-term efficacy of a calcipotriol/betamethasone dipropionate two-compound product in psoriasis vulgaris. Knud Kragballe, MD, Aarhus University Hospital, Aarhus, Denmark, A. Bibby, LEO Pharma, Buckinghamshire, United Kingdom.

83 Comparative assessment of the efficacy of therapy with low and medium. (Note: abstract title reprinted as received.) Yuliya L. Korsakova, PhD, Vladimir V. Badokin, Russian Medical Academy of Post-Graduate Study, Moscow, Russia.


85 Intensive therapy of psoriatic arthritis. Vladimir V. Badokin, Yuliya L. Korsakova, PhD, Russian Medical Academy of Post-Graduate Study, Moscow, Russia.

86 The advantages of topical treatment with the two-compound product calcipotriol/betamethasone dipropionate and calcipotriol cream in psoriasis patients. C. Giurceanu, MD, Ph.D. Giurceanu, C. Enacheu, I. Nedelicu, V. Chiti, 1st Dermatology Clinic, Clinical Polyclinica, Bucharest, Romania.

87 Correlation of lipid parameters to the severity of psoriasis. Andreas Colman, Mathias Brügel, Joachim Thiery, Michael Stichler, University of Leipzig, Leipzig, Germany.

88 Methods for assessing efficacy of psoriasis therapies. Charles N. Ellis, MD, University of Michigan Dermatology, University of Michigan Hospital, Ann Arbor, MI, United States, John Birtle-Jones, MRCP, Walsgrave Hospital, Coventry, United Kingdom.

89 Juvenile psoriatic arthritis. Robert Stawowski, MD, Lidia Rutkowska-Sak, Institute of Rheumatology, Warsaw, Poland.

90 Pooled, comparative analysis of one, two and four week efficacy of placebo and calcipotriol in psoriasis vulgaris. Mark Lebwohl, MD, Mount Sinai School of Medicine, New York, NY, United States, C. Ganslandt, PhD, LEO Pharma, Ballerup, Denmark.

91 Early changes in markers of bone metabolism in patients with psoriatic arthritis treated with anti-TNFa therapy: A comparison with rheumatoid arthritis. Adrian Gibbs, MRCP, Barbara Murray, Bea Radovits, Barry Crookshain, Douglas Veale, MD, FRCP, FFCP, Malachi McKenna, Oliver FitzGerald, PhD, St. Vincent’s University Hospital, Dublin, Ireland.

92 Magnetic resonance imaging study assessing the efficacy of anakinra (Kinera) in psoriatic arthritis: Evaluating compartmental-specific synovitis using a novel scoring method. Adrian Gibbs, MRCP, Barry Brennihan, Douglas Veale, MD, FRCP, FCP, Robin Gibney, Oliver FitzGerald, PhD, St. Vincent’s University Hospital, Dublin, Ireland.

93 Efficacy of anakinra (Kinera) in psoriatic arthritis: A clinical and immunohistological study. Adrian Gibbs, MRCP, Barry Brennihan, Douglas Veale, MD, FRCP, FPC, Oliver FitzGerald, PhD, St. Vincent’s University Hospital, Dublin, Ireland.

94 Chronic Hepatitis B reactivation following etanercept therapy in a psoriatic patient. Nicole Seleno-Keb-Gebauer, MD, Karoline Stur, MD, Groeg Stang, Franz Karth Fowler, MD, Dept. of Dermatology, Div. of Immunology, Allergy and Infectious Diseases, Vienna, Austria.

95 Linear nevus psoriasis: A case report. Yong-Kwang Tay, MD, MRCP, Changi General Hospital, Singapore, Singapore.

96 Development and evaluation of PASE: A self-administered Psoriatic Arthritis Screening and Evaluation tool. Elnor Mobdy, MD, Abir Qureshi, MD, MPH, Brigham and Women’s Hospital, Boston, MA, United States, Elaine Husni, MD, MPH, Cleveland Clinic, Cleveland, OH, United States.

97 Classification criteria for psoriatic arthritis: Results from the CASPAR study. Philip Hellwell, PhD, University of Leeds, Leeds, United Kingdom, William Taylor, University of Oxford, Oxford, Wellington, New Zealand.

98 Etanercept 50 mg once/week sustains clinical improvement in patients with psoriasis transferring from 25 mg etanercept twice/week. Anca Serban, Wyeth Research, Collegeville, PA, United States, Jean Paul Ortonne, MD, Hospital de l’Arche, Nice, France, Bora Elekso, University of Alabama, Birmingham, AL, United States, Craig Leonard, MD, St. Louis University, St. Louis, MO, United States, Angelika Jahres, Amgen, Inc., Thousand Oaks, CA, United States.

99 Adalimumab is efficacious in treating skin disease of psoriatic arthritis patients with mild to severe baseline skin involvement: Subanalysis of ADEPT. Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, United States, Dafna D. Gladman, MD, FRCP, University of Toronto, Toronto, Ontario, Canada, Ernest Choy, King’s College, London, United Kingdom, Serge Steinfeld, Erasmus University Hospital, Brussels, Belgium, Renee Perkoll, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, United States.

100 Concurrent efficacy of adalimumab against skin and joint disease in psoriatic arthritis. Christopher Ritchlin, MD, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States, Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, United States, Eric Sasso, Abbott Laboratories, Abbott Park, IL, United States.

101 Efficacy in moderate to severe psoriatic arthritis patients who have escalated dosing due to subtherapeutic response to adalimumab eow. Christopher Ritchlin, MD, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States, Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, United States, Richard G. Langley, MD, Dalhousie University, Halifax, Nova Scotia, Canada, Craig Leonard, MD, Central Dermatology Inc., St. Louis, MO, United States, Darryl Toth, Probity Medical Research, Windsor, Ontario, Canada, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, United States.

102 Recent history of systemic or biologic therapy does not appear to adversely affect adalimumab efficacy and safety in psoriasis. Richard G. Langley, MD, Dalhousie University, Halifax, Nova Scotia, Canada, Craig Leonard, MD, Central Dermatology Inc., St. Louis, MO, United States, Darryl Toth, Probity Medical Research, Windsor, Ontario, Canada, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, United States.
103 Adalimumab efficacy in treatment of moderate to severe chronic plaque psoriasis is sustained throughout 60 weeks, with an acceptable safety profile. Richard G. Langleby, MD, Eastern Canada Cutaneous Research Ltd., Halifax, Nova Scotia, Canada, Craig Leonardi, MD, Central Dermatology Inc., St. Louis, MO, United States, Darryl Toth, Probity Medical Research, Windsor, Ontario, Canada, Martin M. Okun, Abbott Laboratories, Abbott Park, IL, United States.

104 Long-term efficacy, safety and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT. Philip J. Mease, MD, Swedish Medical Center, Seattle, WA, United States, Daifra Gladman, MD, FRCPC, University of Toronto, Toronto, Ontario, Canada, Christopher Ritchlin, MD, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States, Eric Sasso, Abbott Laboratories, Abbott Park, IL, United States.

105 Epidemiology of psoriasis in Kuwait. Khairia Al-Mazeedi, Hejaz Saudi Al-Ajmi, Ameei Hospital, Bayan, Kuwait.

106 Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Maartje Berends, MD, J. Snoek, Peter C.M. van der Kerkhof, MD, PhD, M.G.H. van Oijen, E.M.G.J. de Jong, MD, PhD, J.P.H. Dreinh, MD, PhD, H. Van Krieken, Radboud University Medical Center Nijmegen, Gelderland, The Netherlands.

107 Antiproliferative, antiangiogenic and apoptotic mechanism of phototherapy (PUVA) in psoriatic patients. Romana Ceevic, MD, PhD, Arda Pasic, MD, Jasna Lipovicic, MD, PhD, Jasminka Jako-Razumovic, MD, PhD, Zagreb University Hospital Center, Zagreb, Croatia.

108 A randomized, double-blind, vehicle-controlled study of the efficacy of acitretin with and without the co-administration of 0.1% tacrolimus topical ointment for moderate to severe psoriasis. Alan B. Fleischer, Jr., MD, Steven R. Feldman, MD, PhD, Wake Forest University School of Medicine, Winston-Salem, NC, United States, Andrew A. Nelson, Baltimore, MD, United States, Jennifer Kreij-Manwaring, University of Kansas Medical Center, Kansas City, KS, United States, Joy Willard, M. Ann McCarty, Wake Forest University School of Medicine.

109 Disease activity, radiographic features and bone density in psoriatic and rheumatoid arthritis. Soumya M. Reddy, MD, New York University, Hospital for Joint Diseases, New York, NY, United States, George Reed, PhD, University of Massachusetts, Worcester, MA, United States, Allen Arandarajah, MD, University of Rochester, Rochester, NY, United States, Jeffrey D. Greenberg, MD, MPH, Steven B. Abramson, MD, New York University, Hospital for Joint Diseases, Joel Kremer, MD, Albany, NY, United States, Christopher T. Ritchlin, MD, University of Rochester.

110 A differential effect of calcitriol and calcipotriol on continuous efalizumab in Saudi Arabia. Samir A. T. Hanifah, MD, Abdulla A. Alabani, MD, FRCP, Fahd Al Harthi, MD, Mohamed Al Jamali, MD, Wadha Al Khadi, MD, Yasser Al Qubaisy, MD, Riyadh Armed Forces Hospital, Riyadh, Saudi Arabia.

111 Long-term treatment of 4.5 years with infliximab: A case report of a patient with severe psoriasis. Eyal Yussak, MD, Rabin Medical Center, Holon, Israel, Michael David, MD, Rabin Medical Center, Petah Tikva, Israel, Ian Bank, MD, Sheba Medical Center, Ramat Gan, Israel.

112 Efficacy and safety of 24-week therapy with continuous efalizumab in Saudi Arabia. Samir A. T. Hanifah, MD, Abdulla A. Alabani, FRCP, Fahd Al Harthi, MD, Mohamed Al Jamali, MD, Wadhah Al Khadi, MD, Yasser Al Qubaisy, MD, Riyadh Armed Forces Hospital, Riyadh, Saudi Arabia.

113 Predictors for radiological damage in psoriatic arthritis: Results from a single centre. Dafna D. Gladman, MD, FRCPC, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada, Simon J. Bond, PhD, Institute of Public Health, Cambridge, United Kingdom, Catharine T. Schentag, MSc, University of Toronto, Toronto Western Hospital, Verin T. Farewell, Institute of Public Health.


115 Results of a Phase II study of CNT 1275 in the treatment of psoriasis. Gerald G. Krueger, MD, University of Utah Health Science Center, Salt Lake City, UT, United States, Richard Langley, MD, Dalhouse University, Halifax, Nova Scotia, Canada, Craig Leonardi, MD, St. Louis University Medical School, St. Louis, MO, United States, Mark Ledbohr, MD, Mount Sinai School of Medicine, New York, NY, United States.

116 Infliximab: One year Phase III results. Gerald G. Krueger, MD, University of Utah Health Science Center, Salt Lake City, UT, United States, Steven R. Feldman, MD, PhD, Wake Forest University School of Medicine, Winston-Salem, NC, United States, Gerald D. Weinberg, MD, University of California Irvine Medical Center, Irvine, CA, United States, Alan Menter, MD, Baylor University Medical Center, Dallas, TX, United States.

117 Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Désirée van de Heijde, University Hospital Maastricht, Maastricht, The Netherlands, Dafna D. Gladman, MD, FRCPC, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada, Arthur Kavanaugh, MD, University of California San Diego, La Jolla CA, United States, Christian Antoni, Friedrich-Alexander University Erlangen, Germany, Gerald G. Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States, Cynthia Guzzo, Bei Zhou, L.T. Dooley, Ana Beutler, Centocor Research and Development, Inc., Malvern, PA, United States.

118 Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multicenter, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis. Alice B. Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, United States, Ellen H. Frankel, PhD, Fair Haven Community Health Center, Clinton, NJ, United States, Bruce E. Strober, MD, PhD, New York University School of Medicine, New York, NY, United States, David Fissinger, Dermatology, LLC, Ann Arbor, MI, United States, Seth R. Stevens, MD, Amgen Inc., Thousand Oaks, CA, United States.

119 Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Désirée van de Heijde, University Hospital Maastricht, Maastricht, The Netherlands, Dafna D. Gladman, MD, FRCPC, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada, Arthur Kavanaugh, MD, University of California San Diego, La Jolla CA, United States, Christian Antoni, Friedrich-Alexander University Erlangen, Germany, Gerald G. Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States, Cynthia Guzzo, Bei Zhou, L.T. Dooley, Ana Beutler, Centocor Research and Development, Inc., Malvern, PA, United States.

117 Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multicenter, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis. Alice B. Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, United States, Ellen H. Frankel, PhD, Fair Haven Community Health Center, Clinton, NJ, United States, Bruce E. Strober, MD, PhD, New York University School of Medicine, New York, NY, United States, David Fissinger, Dermatology, LLC, Ann Arbor, MI, United States, Seth R. Stevens, MD, Amgen Inc., Thousand Oaks, CA, United States.

120 Infliximab safety experience: Data from clinical trials in patients with psoriatic disease. Kenneth B. Gordon, MD, Loyola University Medical Center, Maywood, IL, United States, Frank O. Nestle, MD, University Hospital Zurich, Zurich, Switzerland, Cynthia Guzzo, Shu Li, Centocor Research and Development, Inc., Malvern, PA, United States.

121 Treatment w/ infliximab is associated with "major clinical response" in psoriatic arthritis patients treated w/ infliximab: Analysis of two double-blind placebo controlled trials. Arthur Kavanaugh, MD, University of California San Diego, La Jolla, CA, United States, Gerald G. Krueger, MD, University of Utah Health Sciences Center, Salt Lake City, UT, United States, Charles Babira, University of Massachusetts School of Medicine, Worcester, MA, United States, Dale Halper, Houston Institute of Clinical Research, Houston, TX, United States, Pet Gerseus, Limburg University Centre, Belgium & Rheumatology, Maastricht, The Netherlands, Kurt de Vlam, University Hospital Leuven, Leuven, Belgium, Bei Zhou, L. Dooley, Cynthia Guzzo, M. Ann Bala, Anna Beutler, Centocor, Inc., Malvern, PA, United States, Christian Antoni, Friedrich-Alexander University, Erlangen, Germany.


124 Clinical efficacy, safety, and patient-reported outcomes of EDUCATE, a multicenter, community-based, open-label study of the effect of etanercept on skin and joint disease in patients with psoriatic arthritis. Alice B. Gottlieb, MD, PhD, Tufts-New England Medical Center, Boston, MA, United States, Ellen H. Frankel, PhD, Fair Haven Community Health Center, Clinton, NJ, United States, Bruce E. Strober, MD, PhD, New York University School of Medicine, New York, NY, United States, David Fissinger, Dermatology, LLC, Ann Arbor, MI, United States, Seth R. Stevens, MD, Amgen Inc., Thousand Oaks, CA, United States.
Transforming patients’ lives through innovations in psoriatic diseases

Look at that!
Data to refine your treatment focus in rheumatology and dermatology
THE INTERNATIONAL FEDERATION OF PSORIASIS ASSOCIATIONS (IFPA)

WHAT IS IFPA?
IFPA is a non-profit organization of psoriasis associations from around the world. The work of IFPA aims to improve medical care, increase public understanding and improve the lives of people with psoriasis and psoriatic arthritis.

WHAT DOES IFPA DO?
• IFPA provides a place for non-profit psoriasis associations to turn for advice and consultation
• IFPA gives members a place to exchange ideas on how best to improve care and treatment
• IFPA encourages the founding of national psoriasis associations
• IFPA provides a forum for psoriasis associations to report on the research conducted within their country
• IFPA looks for ways to encourage international cooperation to advance research
• IFPA represents the interests of its member associations at international forums
• IFPA monitors the worldwide problems people face when they live with psoriasis and psoriatic arthritis
• IFPA and the member associations celebrate World Psoriasis Day, October 29, every year to raise awareness about the disease

WELCOME TO JOIN IFPA
Join IFPA and be a part of our global voice to campaign on behalf of people who have psoriasis and psoriatic arthritis. IFPA grows stronger with each new member organization and gives us the influence to gain worldwide attention from those who can help us beat psoriasis and psoriatic arthritis.
We have outlined the criteria for membership and provided an application form on our web site www.ifpa-psio.org

CONTACT IFPA
For further information on IFPA and IFPA’s activities, please contact getinfo@ifpa-psio.org